FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
By Annika Kim Constantino
Regulators Approve a Twice-Yearly Shot to Prevent H.I.V. Infection
By Apoorva Mandavilli
FDA approves powerful HIV prevention drug: What to know about Yeztugo
By Benjamin Ryan
FDA Approves a Twice-Yearly Shot to Prevent HIV
By Alice Park
A University of Utah doctor’s research led to a major HIV drug. He worries federal cuts will stop people from getting it.
By Brock Marchant
Full Coverage of this storyGilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline (NASDAQ:GILD)
Buy, Sell, Or Hold GILD Stock?
Gilead Sciences (GILD) Stock Surges Over 49% in a Year, Highlighting Powerful Long-Term Growth
By Akshat Gupta
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
By Maham Fatima
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges
Full Coverage of this storyGilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Kymera suffers Sanofi setback but secures $750M Gilead deal
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
By Mariam E Sunny & Shailesh Kuber
Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
Gilead Sciences (GILD) Anticipates 2025 EPS Impact Due to Kymera Transaction | GILD Stock News
Full Coverage of this storyGilead's CAR-T cell therapy shows promise in deadly brain cancer
By Julie Steenhuysen
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
By Deena Beasley & Julie Steenhuysen
Gilead Short Strangle Could Net $395 In Short Order
By Gavin Mcmaster
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
By Andy Studna
Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks
By Jonathan Stempel, Leslie Adler & Chris Reese
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer
By Emily Kimber
Ins & Outs: New year, new bosses at Sanofi, Gilead, and Roche
By Shreeyashi Ojha
Gilead Stock Dives On A Devastating Potential Call From HHS
By Allison Gatlin
Leadership Lessons from Gilead Sciences CEO Daniel O’Day
By Jonathan Sperling
Cognizant, Gilead Sciences extend partnership for genAI
By Anthony Vecchione
Why Gilead Sciences Stock Is Jumping Today
By Keith Speights
Cancer cell therapy from Arcellx, Gilead shows promise in early data
By Jonathan Gardner
Gilead Sciences 2024: After Veklury
By Joshua Slatko
Gilead Sciences Must Face Consumer Claims Over Older, Lower-Quality Drugs, Court Rules
By Connor Lynch
Access questions hang over Gilead's HIV shot
By Maya Goldman
This company stands out for investors looking to invest in US markets - Investing Abroad News
By sunil dhawan